EUVIMEDEUVIMED entdecken
Crossref

Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease

Juma A Mohamedi iD, Yannick Hoffert, Nick Geukens, Jean-François Rahier, Edouard Louis iD, Filip Baert, Pieter Dewint, Guy Lambrecht, Peter Bossuyt iD, Raphael Z Sangeda iD, Marc Ferrante iD, Denis Franchimont und 2 weitere

Alimentary Pharmacology & Therapeutics · 25.10.2026

DOI: 10.1111/apt.71062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 25.10.2026. Verfasst von Juma A Mohamedi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: VLIRUOS, Fonds Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The value of therapeutic drug monitoring during infliximab induction remains uncertain. We evaluated whether baseline infliximab clearance and early exposure metrics identify candidates for potential early proactive therapeutic drug monitoring during induction in inflammatory bowel disease.

Methods

We analysed a multicenter Phase 4 study in which adults with Crohn's disease and ulcerative colitis initiated standard infliximab therapy (5 mg/kg at Weeks 0, 2, 6, 14, 22 and 30) with predefined peak, intermediate and trough sampling. A population pharmacokinetic model characterized disposition and covariates. Logistic regression assessed exposure–response relationships. The primary outcome was week‐30 combined remission (Crohn's disease: Harvey–Bradshaw Index ≤ 4; ulcerative colitis: Partial Mayo score ≤ 2; with faecal calprotectin < 100 μg/g and C‐reactive protein ≤ 5 mg/L).

Results

Seventy‐five participants (33 female; median age 39 years, interquartile range 28–52) contributed pharmacokinetic data. Sixty‐three were evaluable for exposure–response analyses. Twelve participants (19%) achieved combined remission (7/35 Crohn's disease; 5/28 ulcerative colitis). Lower serum albumin, higher body weight, and antibodies to infliximab increased clearance. In ulcerative colitis, baseline clearance and model‐predicted week‐6 trough concentration showed strong discrimination for combined remission (area under the receiver operating characteristic curve 0.88, 95% confidence interval 0.75–1.00; and 0.86, 0.69–1.00, respectively). Baseline clearance > 0.28 L/day and week‐6 trough ≤ 21.6 mg/L identified high‐risk subgroups with few remissions (0/18 and 1/20, respectively, p < 0.05). No robust predictors were identified in Crohn's disease.

Conclusions

A pragmatic, risk‐stratified, model‐informed approach centered on baseline clearance and early troughs may guide personalized infliximab induction in ulcerative colitis. External validation is warranted. Trial Registration EudraCT number: 2015‐004618‐10

Schlagwörter

Stichwörter der Autor:innen

inflammatory bowel diseaseinfliximabpersonalized dosing

Autor:innen und Institutionen

  • Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
  • Department of Pharmaceutics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • PharmAbs, The KU Leuven Antibody Center, KU Leuven, Leuven, Belgium.
  • Department of Gastroenterology, CHU Namur, Yvoir, Belgium.
  • Department of Gastroenterology, CHU Liège, Liège, Belgium.
  • Department of Gastroenterology, AZ Delta, Roeselare, Belgium.

ORCID-Profile: Juma A Mohamedi, Edouard Louis, Peter Bossuyt, Raphael Z Sangeda, Marc Ferrante, Claire Liefferinckx, Erwin Dreesen

Förderung

  • VLIRUOS
  • Fonds Wetenschappelijk Onderzoek

Zitieren

APA

Mohamedi, J. A., Hoffert, Y., Geukens, N., Rahier, J. F., Louis, E., Baert, F., Dewint, P., Lambrecht, G., Bossuyt, P., Sangeda, R. Z., Ferrante, M., Franchimont, D., Liefferinckx, C., & Dreesen, E. (2026). Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.71062

Vancouver

Mohamedi JA, Hoffert Y, Geukens N, Rahier JF, Louis E, Baert F, et al. Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.71062

BibTeX
@article{Mohamedi2026,
  author = {Mohamedi, Juma A and Hoffert, Yannick and Geukens, Nick and Rahier, Jean-François and Louis, Edouard and Baert, Filip and Dewint, Pieter and Lambrecht, Guy and Bossuyt, Peter and Sangeda, Raphael Z and Ferrante, Marc and Franchimont, Denis and Liefferinckx, Claire and Dreesen, Erwin},
  title = {Baseline Clearance and Early Troughs Identify Candidates for Early Therapeutic Drug Monitoring During Infliximab Induction in Inflammatory Bowel Disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.71062}
}
Kostenlos starten →